

Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency

- *In alignment with Global Reporting Initiative (GRI) information requirements and recommendations, the report was verified by an external independent firm and approved by Grifols' Board of Directors on April 27, 2018.*
- *The report aims to offer Grifols' stakeholders a true and comprehensive overview of its social, environmental and economic performance in 2017, within the framework of the commitments assumed in the Social Corporate Responsibility Policy.*
- *Grifols' annual corporate governance report, financial statements and specific information on activities related to its foundations and Grifols' Academies are public documents, further underscoring the company's commitment to transparency.*

Barcelona (Spain), May 23, 2018.- Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), a global company that enhances the health and well-being of patients through the development of life-saving plasma-derived medicines, clinical diagnostics and pharmaceutical specialities for hospital use, today announced the publication of its 2017 Corporate Responsibility Report. The report highlights Grifols' firm commitment and pledge of transparency to its stakeholders, which include, among others, donors, patients, medical professionals, employees and society as a whole.

The information contained therein offers an in-depth view of Grifols' social engagement initiatives, ongoing training, commitment to inclusion and diversity, environmental actions, and respect for human rights and business ethics in compliance with Sustainability Reporting Standards of Global Reporting Initiative (GRI Standards).

Grifols' Corporate Responsibility Report covers the 2017 fiscal year, using a materiality analysis as its basis. The report was verified by an external independent company and approved by Grifols' Board of Directors on April 27, 2018.

Grifols aspires to continue to contribute toward economic, environmental and social progress on local, regional and global levels. The information relating to its 2017 performance is contextualized within the framework of the regions where it operates.

The report is available for download on Grifols' website: www.grifols.com

GRIFOLS

Investors' contact:

Investor Relations Department

inversores@grifols.com - investors@grifols.com

Phone number: +34 93 571 02 21

Media contact:

Raquel Lumbreras

raquel_lumbreras@duomocomunicacion.com

Borja Gómez

borja_gomez@duomocomunicacion.com

Duomo Comunicación - Grifols Press Office

Phone number: +34 91 311 92 89 - +34 91 311 92 90

About Grifols

Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.

Grifols' three main divisions - Bioscience, Diagnostic and Hospital - develop, produce and market innovative products and services that are available in more than 100 countries.

With a network of 190 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.

Grifols is headquartered in Barcelona, Spain and has 18,300 employees in 30 countries.

In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).

For more information, visit www.grifols.com
